The question of whether MK-677 is a peptide or steroid comes up constantly because the compound gets marketed alongside both categories. The honest answer is neither: MK-677, known by its research name ibutamoren, is a small molecule, not a chain of amino acids and not a steroid hormone derivative.
The Compound Universe take: MK-677 is neither a peptide nor a steroid: a small-molecule ghrelin receptor agonist whose two human RCTs cut opposite ways, modest lean-mass and GH/IGF-1 gains in healthy older adults, a cardiac-risk signal strong enough to stop the hip-fracture arm early. That split record, not the marketing, should set expectations.
The core human RCT enrolled healthy older adults, not bodybuilders.
New here? See the peptides for growth hormone overview first.
What MK-677 (ibutamoren) actually is
Merck developed MK-677 in the 1990s as an orally active alternative to injectable GH secretagogue peptides. It mimics ghrelin, the “hunger hormone,” by binding the ghrelin receptor (GHS-R1a) to trigger a pulse of growth hormone and downstream IGF-1 [1][2]. That shared mechanism is the source of the peptide-or-steroid confusion below.
| Question | Answer | Evidence tier | Source type |
|---|---|---|---|
| Is it a peptide? | No, it is a small-molecule, non-peptide compound | Structural / mechanistic | Peer-reviewed structural biology [1] |
| Is it a steroid? | No, it does not bind androgen receptors | Mechanistic / review | Peer-reviewed review [4] |
| What is it, then? | An orally active ghrelin receptor agonist / GH secretagogue | Human RCT | Ann Intern Med RCT [2] |
| Is it FDA-approved? | No, not for any indication | Regulatory | FDA correspondence / warning letters [6] |
Why MK-677 is not a peptide or a steroid
Not a peptide: no amino acid chain
A peptide, by strict definition, is a short chain of amino acids linked by peptide bonds; BPC-157, ipamorelin, and CJC-1295 fit that definition, MK-677 does not. It is a synthetic organic molecule engineered for oral stability rather than injectable delivery [1][3], built to survive digestion while restoring growth-hormone pulsatility comparable to younger adults [2][3]. That is why researchers file it under “peptidomimetic,” not peptide.
Ipamorelin hits that same ghrelin receptor as a true amino-acid peptide.
Not a steroid or SARM: no androgen receptor binding
Anabolic-androgenic steroids and SARMs (selective androgen receptor modulators) bind the androgen receptor that testosterone activates; MK-677 has no meaningful affinity for it [4]. Grouping it with SARMs, as retail sites often do, is a mechanistic error, not a marketing shortcut.
HPTA axis and testosterone: what stays intact
MK-677 raises growth hormone and IGF-1 through the ghrelin receptor, mechanistically separate from androgen signaling [1][2]. It does not suppress luteinizing hormone or follicle-stimulating hormone the way anabolic steroids do, and the HPTA axis is not directly shut down [4].
What the human research actually shows
The clearest data comes from a randomized, placebo-controlled trial in healthy older adults, published in Annals of Internal Medicine [2]; a separate elderly hip-fracture trial found a cardiac-vulnerability signal serious enough to end that arm early [5]. Both feed the same GH/IGF-1 mechanism, but neither tells the whole story alone.
| Study | Population | Key finding | Evidence tier |
|---|---|---|---|
| Nass et al. [2] | Healthy older adults | Higher GH/IGF-1, modest lean-mass gain; edema and appetite increase | Human RCT |
| Murphy et al. [3] | Healthy adults, short-term fasting | Reversed diet-induced catabolism | Human, short-term metabolic study |
| Adunsky et al. [5] | Elderly, hip-fracture recovery | Higher CHF rate, elevated glucose and blood pressure; arm stopped early | Human RCT (cardiac-vulnerable elderly) |
Compound Universe take: Population, not just compound, drove the divergent outcomes here: the cardiac-risk signal came from a cardiac-vulnerable, hip-fracture cohort; the lean-mass gain came from a separate healthy-older-adult cohort [2][5]. Treat these as two population-specific readouts, not one blended verdict for MK-677 generally.
Read this before the hype: MK-677 is not FDA-approved for any indication as of July 2026 and is not a legal dietary supplement in the United States; the FDA has taken the position that it is excluded from the dietary supplement definition because it was previously authorized for drug investigation. It is sold as a “research chemical,” and the World Anti-Doping Agency lists ibutamoren by name on its Prohibited List. This article summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use.
MK-677 legal and regulatory status as of July 2026
Merck ran MK-677 through Phase 2 trials but never filed for FDA approval; no ibutamoren product carries marketing authorization today [6]. The FDA has since issued warning letters over ibutamoren products, including a 2021 letter flagging “SARMs” and ibutamoren powder [6].
MK-677 carries no federal scheduling, so personal possession is not treated like a DEA-scheduled substance. Selling it for human use is separate, and the FDA’s exclusion of it from the dietary supplement definition narrows that path; see the broader legal status of research peptides for how this compares across the category. Athletes get no gray area: WADA bans ibutamoren outright under its growth hormone secretagogue section (S2), at all times, in and out of competition.
Compound Universe take: A compound can clear Phase 2 and still stop short of a pharmacy shelf; MK-677 did exactly that, and no federal schedule closes the gap WADA already closed with an outright ban. Unscheduled is not unrestricted: this is a stalled drug candidate wearing a supplement-store label.
| Attribute | Status | Evidence maturity | Regulatory note |
|---|---|---|---|
| Molecule class | Non-peptide small molecule | Structural | Not a peptide, not a steroid |
| Primary mechanism | Ghrelin receptor (GHS-R1a) agonist | Human + structural | Same target as ghrelin |
| GH / IGF-1 effect | Increases pulsatile GH and IGF-1 | Human RCT | Not FDA-approved |
| Androgen receptor | No meaningful binding | Mechanistic review | Distinct from steroids/SARMs |
| Athletic status | Prohibited at all times | Regulatory | WADA S2 category |
FDA and WADA run two different fights, and neither favors MK-677.
Key takeaways
- MK-677 is a non-peptide small molecule, engineered to survive oral dosing while activating the same ghrelin receptor pathway peptide GH secretagogues use [1].
- It is not a steroid or SARM, because it does not meaningfully bind the androgen receptor or suppress the HPTA axis those compounds do [4].
- Human trial data shows real GH and IGF-1 increases alongside transient edema, increased appetite, and in vulnerable elderly patients, elevated blood glucose and cardiac risk [2][5].
- MK-677 is not FDA-approved and not a legal dietary supplement as of July 2026, and it remains a named entry on WADA’s Prohibited List [6].
- Classifying MK-677 correctly (non-peptide secretagogue, not steroid) matters because it changes what evidence and safety data apply.
Frequently asked questions
Is MK-677 a peptide?
No. MK-677 (ibutamoren) is a synthetic non-peptide small molecule. It activates the same ghrelin receptor that peptide GH secretagogues use, but is not built from amino acids and does not meet the chemical definition of a peptide.
Is MK-677 a steroid?
No. MK-677 does not bind the androgen receptor, unlike anabolic-androgenic steroids or SARMs. Its effects run through the ghrelin receptor and growth hormone axis.
What class of drug is MK-677 then?
Researchers classify it as a non-peptide (peptidomimetic) growth hormone secretagogue and ghrelin receptor agonist, its own category, separate from peptides and steroids.
Is MK-677 legal to buy or use in 2026?
It is not FDA-approved, and the FDA holds that it does not qualify as a dietary supplement. It carries no federal scheduling, but selling it commercially has drawn FDA warning letters, and WADA bans it for competitive athletes.
Does MK-677 suppress natural testosterone like a steroid would?
Available research indicates it does not meaningfully suppress luteinizing hormone or follicle-stimulating hormone, unlike anabolic steroids: one of the clearer mechanistic differences between MK-677 and true steroid compounds.
What are the documented risks of MK-677?
Human trials report transient lower-extremity edema, increased appetite, and mild muscle soreness in most participants. In cardiac-vulnerable elderly populations, one trial found higher rates of congestive heart failure and elevated blood glucose, a documented safety signal.
MK-677 sits at the intersection of ghrelin-receptor pharmacology and growth-hormone-axis research, distinct from true peptide secretagogues like GHRP-6 and ipamorelin and further still from androgen-receptor compounds like steroids and SARMs; Compound Universe tracks the mechanistic literature, the human trial record, and current FDA/WADA status together, so the classification question gets a precise answer instead of a marketing one.
To close the loop: is MK-677 a peptide or steroid? Neither. It is a distinct, non-peptide growth hormone secretagogue with its own mechanism, its own human trial record, and its own unresolved regulatory status as of July 2026, and treating it as either a peptide or a steroid misreads the actual chemistry.
Compare next: MK-677 vs CJC-1295
References
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nature Communications. PMC8568970 / DOI: 10.1038/s41467-021-26735-5.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial. Annals of Internal Medicine. PMC2757071 / DOI: 10.7326/0003-4819-149-9-200811040-00003.
- Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism in man. PMID 9467534.
- Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. PMID 32257855.
- Adunsky A, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics. 2011. DOI: 10.1016/j.archger.2010.10.004.
- FDA Warning Letter, Umbrella (05/18/2021), addressing SARMs and ibutamoren products marketed for human use; FDA position that ibutamoren is excluded from the dietary supplement definition. fda.gov warning letter database.